Vaxcell-Bio Therapeutics Co. Ltd

323990 · KQ · Healthcare / Biotechnology

3,970.00KRW-100.00 (-2.46%)

Price History

Full chart

Market Stats

Previous Close4,070.00

Open4,100.00

Day Range3,945.00 – 4,235.00

52-Week Range3,350.00 – 11,520.00

Volume327.25K

Market Cap99.30B

P/E (TTM)0.00

Forward P/E0.00

Dividend Yield0.00%

Beta3.72

50-Day Avg4,242.50

200-Day Avg6,721.18

About

Vaxcell-Bio Therapeutics Co., Ltd. develops and anticancer immunotherapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea.

Company Details

SectorHealthcare
IndustryBiotechnology
Employees58
Headquarters98-1 Sandan-gi, Hwasun-eup, South Korea, Korea
Websitehttps://www.vaxcell-bio.com

Financials

Income Statement

Currency: KRW	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	0	0	0	0	0	13.72M	1.90B	7.06B
Growth (%)	-	-	-	-	-	-	+13737.27%	+271.59%
Cost of Revenue	0	0	0	0	0	6.60M	1.53B	6.16B
Gross Profit	0	0	0	0	0	7.13M	364.77M	893.11M
Gross Margin	-	-	-	-	-	51.94%	19.21%	12.66%
Operating Expense	2.42B	4.01B	4.25B	5.90B	8.22B	11.51B	15.42B	16.38B
Operating Income	-2.42B	-4.01B	-4.25B	-5.90B	-8.22B	-11.51B	-15.05B	-15.49B
Operating Margin	-	-	-	-	-	-83848.01%	-792.76%	-219.51%
EBITDA	-	-	-	-	-6.50B	-9.83B	-8.93B	-10.93B
EBITDA Margin	-	-	-	-	-	-71635.17%	-470.41%	-154.95%
Net Income	-6.45B	-1.25B	-3.98B	-4.76B	-6.83B	-10.27B	-10.62B	-13.34B
Net Income Margin	-	-	-	-	-	-74865.79%	-559.45%	-189.05%
R&D	-	-	987.21M	1.76B	2.17B	4.92B	6.04B	5.64B
R&D as % of Total Revenue	-	-	-	-	-	35844.53%	318.09%	79.88%
Interest Expense	0	0	37.86M	28.92M	18.12M	43.66M	225.12M	224.61M
Interest Expense % of Total Revenue	-	-	-	-	-	318.18%	11.85%	3.18%

Balance Sheet

Currency: KRW	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	12.26B	10.04B	35.50B	31.28B	24.16B	84.98B	76.94B	66.90B
Total Liabilities	24.45B	964.46M	830.10M	1.20B	835.78M	1.49B	4.95B	5.77B
Total Equity	-12.20B	9.07B	34.67B	30.08B	23.33B	83.49B	71.99B	61.13B
Cash	341.43K	0	9.90B	27.31B	389.66M	9.05B	7.82B	6.22B
Total Debt	12.28B	300.63M	152.75M	-	-	-	-	-

Cash Flow

Currency: KRW	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-1.99B	-3.59B	-3.30B	-4.66B	-6.04B	-9.42B	-10.70B	-10.63B
Investing Cash Flow	-6.47B	2.07B	-20.05B	-3.24B	4.33B	-51.79B	10.32B	-
Financing Cash Flow	11.99B	1.14B	29.18B	304.75M	-207.85M	69.87B	-848.85M	-
Capital Expenditure	467.05M	902.70M	26.91M	2.23B	290.21M	198.50M	4.07B	6.78B
Free Cash Flow	-	-	-3.33B	-6.89B	-6.33B	-9.62B	-14.76B	-17.41B
FCF to OCF	-	-	100.97%	147.79%	104.80%	102.11%	138.00%	163.79%

Earnings

Report Date	Sep 30, 2020	Mar 17, 2021	May 17, 2021	Jun 30, 2021	Sep 30, 2021	Dec 31, 2021	Mar 31, 2022	Jun 30, 2022	Sep 30, 2022	Dec 31, 2022	May 12, 2023	Aug 14, 2023	Nov 13, 2023	Mar 19, 2024	May 16, 2024	Aug 14, 2024	Nov 11, 2024	May 15, 2025	Aug 12, 2025	Nov 12, 2025	Dec 31, 2025	May 13, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	-44.32	-71.13	-58.00	-65.83	-64.74	-66.89	-83.41	-65.47	-83.12	-105.82	-147.32	-163.86	-154.04	-118.42	-106.71	-106.47	-104.89	-121.11	-164.93	-116.25	-182.07	-171.27	-174.61
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	-	-	-	-	-	-	-	-	-	-	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	After-hours	Pre-market	Pre-market	Pre-market	-	Pre-market	-

Key Statistics & Ratios

Market Cap99.30B

Enterprise Value83.91B

Trailing P/E0.00

Forward P/E0.00

Price / Sales15.01

Price / Book1.83

Revenue (TTM)40.36M

Gross Profit (TTM)17.26M

EBITDA-11.78B

Profit Margin0.00%

Operating Margin-730.94%

Return on Equity-20.50%

Return on Assets-14.50%

Shares Outstanding23.17M

Shares Float18.23M

Beta3.72

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Stock Splits

Nov 10, 20236:5
Sep 20, 20233580:3237
Dec 30, 20202:1